nach oben

Erschienen in:

01.08.2010 | Original Article

Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study

verfasst von: Dominique Koensgen, Guelten Oskay-Oezcelik, Ioanna Katsares, Ulla Walle, Christine Klapp, Alexander Mustea, Dirk Stengel, Franz Porzsolt, Werner Lichtenegger, Jalid Sehouli, on behalf of the Nord-Ostdeutschen Gesellschaft für Gynäkologische Onkologie (NOGGO) working group “Quality of life”

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

Quality of life (Qol) represents a relevant end point in the clinical management of advanced ovarian cancer (AOC). However, there exist only a few specific instruments which have been designed for patients with ovarian cancer. The aim of this study was to develop a systematic checklist (Berlin Symptom Checklist Ovary (BSCL-O)) as an instrument of Qol for patients with AOC and to discriminate between the frequency and the importance of symptoms.

Patients and methods

The main symptoms were identified in a phase I study via free interviews of five patients with ovarian cancer (OC) as well as five medical doctors, family dependants, and care workers. In the phase II study, the capability of BSCL-O was evaluated by questionnaire-guided interviews of 200 patients with primary OC, recurrent OC, metastasized breast cancer, and benign ovarian tumors.

Main results

In phase I, 36 main symptoms were identified. In phase II, 7,200 answers from 98.5% of all patients were evaluable. Of the 36 symptoms of the BSCL-O, 23 revealed clinical relevance. There was a correlation of frequency and importance of symptoms (p < 0.05). The symptoms of the BSCL-O were deemed twice as strenuous in patients with recurrent OC.

Conclusions

The BSCL-O can measure Qol of patients with OC. The BSCL-O is being validated in a phase III study.

Anderson B (1994) Quality of life in progressive ovarian cancer. Gynecol Oncol 55:151–155

Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA et al (2001) Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 19(6):1809–1817PubMed

Bullinger M (1996) Methoden zur Lebensqualitätsbewertung in der Onkologie. Forum Deutsche Krebsgesellschaft 11:210–216

Calhoun EA, Welshman EE, Chang CH et al (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741–748CrossRefPubMed

Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed

Coates A, Dillenbeck CF, McNeil DR et al (1983) On the receiving end-II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol 19:1633–1637CrossRefPubMed

Cull A, Howat S, Greimel E et al (2001) Development of a European organization for research and treatment of cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37:47–53CrossRefPubMed

Ersek M, Ferrell B, Dow K et al (1997) Quality of life in women with ovarian cancer. West J Nurs Res 19:334–350CrossRefPubMed

Fish L, Lewis B (1999) Quality of life issues in the management of ovarian cancer. Semin Oncol 26:32–39PubMed

10.

Greimel ER, Bjelic-Radisic V, Pfisterer J et al (2006) Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 24(4):579–586CrossRefPubMed

11.

Greimel E, Bottomley A, Cull A et al (2003) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 39:1402–1408CrossRefPubMed

12.

Guidozzi F (1993) Living with ovarian cancer. Gynecol Oncol 50:202–207CrossRefPubMed

13.

Jacobs I, van Nagell J, DePriest P Jr (1998) Screening for epithelial ovarian cancer. In: David M, Gershenson W, Mcguire P (eds) Ovarian cancer: controversies in management. Medical Division of Pearson Professional Limited, New York, pp 1–15

14.

Le T, Leis A, Pahwa P et al (2004) Quality of life evaluations of caregivers of ovarian cancer patients during chemotherapy treatment. J Obstet Gynaecol Can 26(7):627–631PubMed

15.

Montazeri A, McEwen J, Gillis C (1996) Quality of life in patients with ovarian cancer: current state of research. Support Care Cancer 4:169–179CrossRefPubMed

16.

Moore DH (1994) Ovarian cancer in the elderly patient. Oncology (Williston Park) 8:21–30

17.

Oskay-Ozcelik G, Sehouli J (2009) Pros and cons for systemic therapy in recurrent ovarian cancer. Anticancer Res 29(7):2831–2836PubMed

18.

Portenoy R, Kornblith A, Wong G (1994) Pain in ovarian cancer patients. Cancer 74:907–915CrossRefPubMed

19.

Portenoy R, Thaler H, Kornblith A (1994) The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326–1336CrossRefPubMed

20.

Sun CC, Bodurka DC, Weaver CB et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219–227CrossRefPubMed

21.

Wenzel L, Huang HQ, Monk BJ et al (2005) Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 23(24):5605–5612CrossRefPubMed

22.

Willemse P, van Lith J, Mulder N (1990) Risk and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis. Eur J Cancer 26:345–352CrossRefPubMed

Titel: Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study
verfasst von: Dominique Koensgen
Guelten Oskay-Oezcelik
Ioanna Katsares
Ulla Walle
Christine Klapp
Alexander Mustea
Dirk Stengel
Franz Porzsolt
Werner Lichtenegger
Jalid Sehouli
on behalf of the Nord-Ostdeutschen Gesellschaft für Gynäkologische Onkologie (NOGGO) working group “Quality of life”
Publikationsdatum: 01.08.2010
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 8/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-009-0733-0

Springer Medizin

Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study